Onderzoeker
Julia Katharina Schwarze
- Trefwoorden:Geneeskunde
- Disciplines:Andere basiswetenschappen niet elders geclassificeerd
Affiliaties
- Laboratorium Moleculaire Oncologie (Onderzoeksgroep)
Lid
Vanaf22 mrt 2021 → Heden - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf4 sep 2018 → Heden - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf11 mei 2018 → Heden - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf28 sep 2015 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 jun 2022 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf8 apr 2019 → 31 mei 2022 - Interne Geneeskunde (Departement)
Lid
Vanaf1 sep 2018 → 30 sep 2022 - Medische Oncologie (Departement)
Lid
Vanaf2 jul 2018 → 31 aug 2018 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 jun 2018 → 31 mei 2022 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf21 sep 2012 → 26 jun 2014
Publicaties
1 - 10 van 28
- Current "state of the art" on dendritic cell-based cancer vaccines in melanoma(2023)
Auteurs: Julia Katharina Schwarze, Xenia Geeraerts, Sandra Tuyaerts, Bart Neyns
Pagina's: 87-93 - Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients(2022)
Auteurs: Julia Katharina Schwarze, Jens Tijtgat, Gil Awada, Louise Cras, Angela Vasaturo, Christopher Bagnall, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, et al.
Pagina's: 1-13 - Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma(2022)
Auteurs: Prachi Bhave, Tasnia Ahmed, Serigne N Lo, Alexander N Shoushtari, Anne Zaremba, Judith M Versluis, Joanna Mangana, Michael Weichenthal, Lu Si, Thierry Lesimple, et al.
- A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors(2022)
Auteurs: Gil Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Vibeke Kruse, Bart Neyns
Pagina's: 183-191 - Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1+ Myeloid Dendritic Cells(2022)
Auteurs: Philipp Kalus, Jolien De Munck, Sarah Vanbellingen, Laura Carreer, Thessa Laeremans, Katrijn Broos, Inès Dufait, Julia Katharina Schwarze, Ivan Van Riet, Bart Neyns, et al.
- Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial(2022)
Auteurs: Julia Katharina Schwarze, Soizic Garaud, Yanina Jansen, Gil Awada, Valérie Vandersleyen, Jens Tijtgat, Alexandre de Wind, Paulus Kristanto, Teofila Seremet, Karen Willard-Gallo, et al.
- INTRA-CRANIAL ADMINISTRATION OF CTLA-4 AND PD-1 IMMUNE CHECKPOINT-INHIBITING MONOCLONAL ANTIBODIES IN RECURRENT GLIOBLASTOMA PATIENTS: A MULTI-COHORT ADAPTIVE PHASE I CLINICAL TRIAL(2021)
Auteurs: Johnny Duerinck, Wietse Geens, Julia Katharina Schwarze, Cleo Bertels, Jens Tijtgat, Gil Awada, Freya Vaeyens, Louise Cras, Lynn Nijland, Anne-Marie Vanbinst, et al.
Pagina's: 53-53 - Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells(2021)
Auteurs: Jens Tijtgat, Jolien De Munck, Inès Dufait, Julia Katharina Schwarze, Ivan Van Riet, Lorenzo Franceschini, Karine Breckpot, Joeri Aerts, Bart Neyns, Sandra Tuyaerts
- C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting(2021)
Auteurs: Justine Lauwyck, Aline Beckwée, Arno Santens, Julia Katharina Schwarze, Gil Awada, Valérie Vandersleyen, Sandrine Aspeslagh, Bart Neyns
Pagina's: 371-377 - Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy(2021)
Auteurs: Jens Tijtgat, Julia Katharina Schwarze, Gil Awada, Bart Neyns, Sandrine Aspeslagh
Pagina's: 272-276